The new herpes zoster vaccine “from zero to three years it has an efficacy of 97.4%, I would say exceptionally good and that is confirmed in a relevant way in the long term (7 years) at 84% “. Massimo Galli, director of Infectious Diseases at the Sacco hospital in Milan, in his speech at the webinar ‘Vax on / zoster off-the new paradigm for the prevention of herpes zoster finally available in Italy’.
“Those who work in the clinic cannot fail to have encountered acute pain, and the metameric vesicular rash of herpes zoster – recalled Galli – This is an element that causes a certain annoyance and the importance should not be underestimated. of the consequences of ophthalmic herpes. Herpes zoster has a chronic phase that affects an important percentage of the population, which is seen to put at risk the quality of life. Postherpetic neuralgia is a frequent and not curable complication in an effective way. subsequent period of acute illness, there is an increased risk of cerebral vascular phenomena with severe partial hearing loss “.